Tag: biotech

Healthcare

Is Australia your next best destination for clinical trials?

Australia is home to some of the world’s leading scientists, physicians and healthcare providers. With world-class research capabilities and a thriving biotech sector, the number of clinical trials being conducted in Australia is reportedly growing at around five percent per year, outpacing the United States and the United Kingdom[1]. While Phase III studies have historically…

14 Aug 2018, by Francesca Brewer

Healthcare

Australia’s Capability in Clinical Trials

Earlier this year, Austrade released the new Clinical Trials industry capability report which highlights why Australia is a leading destination for clinical research of new therapeutic products and medical devices. The report showcases Australia’s strengths in the sector—world-class medical research infrastructure, an efficient regulatory system, a strong and stable business environment, and generous tax incentives—that make it…

24 Jul 2018, by Francesca Brewer

Healthcare

Status Quo or No? 2017 Completed Clinical Trials

A completed clinical trial landscape provides a more granular view of how companies are progressing their pipelines and the disease strategies they are pursuing, compared to static pipeline snapshots. Company pipeline depictions lack the underlying intelligence that illustrates just how a candidate progressed, or perhaps disappeared altogether from a disease pipeline. As part of our…

13 Jul 2018, by Francesca Brewer

Banking & Finance

Business

Healthcare

Growing the health tech firms of the future – LaunchVic’s bid to provide better access to capital and mentorship

Health technology is Victoria’s fastest growing source of employment, grossing $30 billion per annum for the state; yet, up to 57 per cent of Victorian health-tech start-ups do not know how to access accelerator or investor support - according to a recent report by LaunchVic. The 'State of HealthTech – Victoria' report revealed that, despite…

20 Jun 2018, by Amy Sarcevic

Healthcare

The case for constant innovation in Australian biotech

Melbourne – 12th October 2010 – The sales contribution from internally developed products is expected to decline from $284 billion in 2009 to $274 billion in 2014, by which time the majority of sales will be derived from externally sourced products. Pharma’s continued need to restock pipelines in order to secure future growth—in the face…

12 Oct 2010, by Informa Insights